Focusing on people at CHR-P, who are typically antipsychotic naive70,71, provides an invaluable opportunity to assess HR and HRV and investigate potential intranasal oxytocin effects in a population that have a high risk of developing psychosis (in particular the brief and limited intermittent psychosis subgroup72–74), without the confounding effects of antipsychotic medication. The gene discussed is OXT; the disease is psychotic disorder.